Meet the world!
TIL-Based Therapy Market is projected to grow at an annualized rate of 40% by 2035
Owing to their tumor-killing capability and therapeutic superiority to conventional therapies, TIL-based therapies are being actively evaluated to treat advance, incurable oncological disorders by various researchers and industry stakeholders
Roots Analysis has announced the addition of “Global TIL-based Therapy Market (2nd Edition), 2023-2035” report to its list of offerings
Given the limitations associated with conventional cancer treatment options, there has been a surge in the need for more effective, safe and versatile alternatives, such as TIL-based therapies. Driven by a promising development pipeline and encouraging clinical trial results, the TIL-based therapy market is likely to carve out a significant share of the cancer immunotherapy market.
Key Market Insights
Over 75 TIL-based therapies are currently approved / under development
Close to 83% of the TIL-based therapies are being evaluated in clinical trials (phase I and above), while 17% of them are in preclinical stage of development. More than 95% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, more than 75% of these are combination therapies.
More than 3,800 patients have been enrolled in nearly 95 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, over 65% are active and still recruiting patients, while more than 25% have already been completed.
Partnership activity within this domain has grown at a CAGR of 29%, between 2015 and 2021
Majority of the agreements related to TIL-based therapies were observed to be R&D agreements, representing close to 40% of the total partnerships. Further, most of the intercontinental, as well as intracontinental, deals have been inked by players based in North America.
Over 2.7 USD billion has been invested by both private and public investors in this domain, since 2013
Industry players raised over USD 1.4 billion in the past 3 years. In addition, majority (37%) of the companies received funding through secondary offering rounds. Further, close to USD 540 million were invested by private firms.
More than 160 patents have been filed / published related to the TCR-based therapies
Close to 75% of the filed / published patents were patent applications, followed by granted patents (25%). Of the total granted applications, more than 95% were filed in North America.
The market is anticipated to grow at a CAGR of 40%, during the period 2022-2035
In 2035, more than 50% of the market revenues are expected to be generated from sales of therapeutics intended for Melanoma. Further, North America and Europe is anticipated to capture close to 90% of the market share, by 2035.
Key Questions Answered
- What is the growth rate of TIL-based therapy market?
- Which region has the highest growth rate in the TIL-based Therapies market?
- How many players are developing TIL-based Therapies?
- Which target indication covers the largest TIL-based therapy market share?
- What is the partnership and collaboration trend in the TIL-based therapy domain?
- What is the current IP landscape of TIL-based therapies market?
The financial opportunity within the TIL-based therapies market has been analyzed across the following segments:
- Head and Neck Carcinoma
- Chronic Lymphocytic Leukemia
- Hepatocellular Carcinoma
- Breast Cancer
- Acute Myeloid Leukemia
- Cervical Carcinoma
Key Geographical Regions
- North America
- Asia Pacific
- Latin America
- Middle East and North Africa
- Rest of the World
The report includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), details about TIL-based product(s), such as information on status of development, technology portfolio (if available), recent developments related to TIL-based therapies and manufacturing capabilities of the players.
- Cellular Biomedicine Group
- Iovance Biotherapeutics
- Lytix Biopharma
- Phio Pharmaceuticals
Read Our Latest Press Release: